GB0913345D0 - New combination 802 - Google Patents

New combination 802

Info

Publication number
GB0913345D0
GB0913345D0 GBGB0913345.5A GB0913345A GB0913345D0 GB 0913345 D0 GB0913345 D0 GB 0913345D0 GB 0913345 A GB0913345 A GB 0913345A GB 0913345 D0 GB0913345 D0 GB 0913345D0
Authority
GB
United Kingdom
Prior art keywords
new combination
new
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0913345.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argenta Discovery Ltd
AstraZeneca AB
Original Assignee
Argenta Discovery Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Discovery Ltd, AstraZeneca AB filed Critical Argenta Discovery Ltd
Priority to GBGB0913345.5A priority Critical patent/GB0913345D0/en
Publication of GB0913345D0 publication Critical patent/GB0913345D0/en
Priority to PCT/GB2010/051243 priority patent/WO2011012897A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0913345.5A 2009-07-31 2009-07-31 New combination 802 Ceased GB0913345D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0913345.5A GB0913345D0 (en) 2009-07-31 2009-07-31 New combination 802
PCT/GB2010/051243 WO2011012897A1 (en) 2009-07-31 2010-07-29 New combinations for the treatment of asthma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0913345.5A GB0913345D0 (en) 2009-07-31 2009-07-31 New combination 802

Publications (1)

Publication Number Publication Date
GB0913345D0 true GB0913345D0 (en) 2009-09-16

Family

ID=41129408

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0913345.5A Ceased GB0913345D0 (en) 2009-07-31 2009-07-31 New combination 802

Country Status (2)

Country Link
GB (1) GB0913345D0 (en)
WO (1) WO2011012897A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52557B (en) 2008-02-06 2013-04-30 Pulmagen Therapeutics (Synergy) Limited UNITS
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2934594B1 (en) 2012-12-18 2019-09-04 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities .
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 a salt of 2-amino-1-hydroxyethyl-8-hydroxyquinoline-2(1H)-one derivative having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activity
CN103141490B (en) * 2013-03-06 2015-09-16 浙江省亚热带作物研究所 N6-(2-ethoxy) adenosine is preparing the application in crop insecticide reagent
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 Salt of 2-amino-1-hydroxyethyl-8-hydroxyquinoline-2(1H)-one derivative having activity of both a muscarinic receptor antagonist and a β2 adrenergic receptor agonist
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
WO2017097568A1 (en) 2015-12-09 2017-06-15 Sabic Global Technologies B.V. Process for the preparation of polyolefin-based graft copolymers comprising a first long chain branched polyolefin block and one or multiple polymer side chains
EP3387046B1 (en) 2015-12-09 2019-12-25 SABIC Global Technologies B.V. Process for the preparation of polyolefin-based graft copolymers comprising a first functionalized short chain branched polyolefin block and one or multiple polymer side chains
WO2018059537A1 (en) * 2016-09-30 2018-04-05 四川海思科制药有限公司 Diazaspiro[5.5]undecane derivative and use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2392472A1 (en) 1999-11-24 2001-05-31 Takeda Chemical Industries, Ltd. Use of disease-associated gene
WO2001047886A1 (en) 1999-12-24 2001-07-05 F. Hoffmann-La Roche Ag Nitrile derivatives as cathepsin k inhibitors
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CO5300399A1 (en) 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
HK1052509B (en) 2000-08-14 2007-09-07 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
SE0100902D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0102617D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0104251D0 (en) 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
SE0104331D0 (en) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
AR038703A1 (en) 2002-02-28 2005-01-26 Novartis Ag DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS AN INHIBITOR OF QUINASA P I 3
AR039385A1 (en) 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
SE0300092D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (en) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
KR20060056444A (en) 2003-06-19 2006-05-24 제내라 코포레이션 Mucin synthesis inhibitor
CN100393700C (en) 2003-06-30 2008-06-11 麦克弗罗斯特(加拿大)公司 cathepsin cysteine protease inhibitor
SE0301963D0 (en) 2003-07-02 2003-07-02 Astrazeneca Ab New compounds
SA04250253B1 (en) 2003-08-21 2009-11-10 استرازينيكا ايه بي Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
KR101190912B1 (en) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Heterocyclic inhibitors of mek and methods of use thereof
US20080255162A1 (en) 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
SE0401762D0 (en) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JP5258299B2 (en) 2004-12-23 2013-08-07 ガルデルマ・リサーチ・アンド・デヴェロップメント Novel ligands that modulate RAR receptors and their use in human pharmaceuticals and cosmetics
WO2006091112A1 (en) 2005-02-22 2006-08-31 Genesis Reasearch And Development Corporation Limited Compositions for the delivery of rna interference molecules and methods for their use
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
CA2635830A1 (en) 2006-01-23 2007-07-26 Laboratoires Serono S.A. Thiazole derivatives and use thereof
TW200745084A (en) * 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
UY30267A1 (en) 2006-04-13 2007-11-30 Astrazeneca Ab NEW DERIVATIVES OF THIOXANTINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
US7772233B2 (en) 2006-04-19 2010-08-10 Merck Serono, S.A. Arylamino N-heteroaryl compounds as MEK inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
WO2007144198A2 (en) 2006-06-16 2007-12-21 Umc Utrecht Holding B.V. Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
BRPI0714463A2 (en) 2006-07-19 2013-04-02 Astrazeneca Ab tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
US7981898B2 (en) 2006-09-07 2011-07-19 Parion Sciences, Inc. Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
WO2008064136A2 (en) 2006-11-17 2008-05-29 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
SE0602739L (en) 2006-12-18 2008-03-25 Nilar Int Ab A system for reducing power in a battery stack arrangement, and a vehicle equipped with such a system
SA08280783B1 (en) 2007-01-11 2011-04-24 استرازينيكا ايه بي Pyridopyrimidine Derivatives as PDE4 Inhibitors
GB0703999D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
UA98961C2 (en) 2007-06-27 2012-07-10 Астразенека Аб Pyrazinone derivatives and their use in the treatment of lung diseases
WO2009037503A2 (en) * 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
NZ584160A (en) 2007-10-04 2011-05-27 Astrazeneca Ab Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
RS52557B (en) * 2008-02-06 2013-04-30 Pulmagen Therapeutics (Synergy) Limited UNITS

Also Published As

Publication number Publication date
WO2011012897A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
GB0913345D0 (en) New combination 802
GB0900404D0 (en) New compounds 4
GB0912946D0 (en) New compounds 5
GB0811099D0 (en) New combination 376
GB0900870D0 (en) Loo 2
EP2513131A4 (en) Novel 3´-deoxy-3´-methylidene- -l-nucleosides
GB0808709D0 (en) New combination 295
GB0901941D0 (en) 1007
GB0902804D0 (en) Fusebox 2
GB0903160D0 (en) Fusebox 4
GB0916350D0 (en) Flexi-bend 2000
GB0921324D0 (en) Guttergrow 2
GB0916463D0 (en) Concept 40
GB0916457D0 (en) Concept 36
GB0916461D0 (en) Concept 38
GB0900055D0 (en) Concept 46
GB0911960D0 (en) Concept 47
GB0916470D0 (en) Concept 50
GB0911961D0 (en) Concept 48
GB0913052D0 (en) Concept 46
GB0916471D0 (en) Concept 51
GB0916447D0 (en) Concept 22
GB0916473D0 (en) Concept 52
GB0916474D0 (en) Concept 53
GB0916475D0 (en) Concept 54

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)